The Contribution of VKORC1 and CYP2C9 Genetic Polymorphisms and Patients' Demographic Characteristics with Warfarin Maintenance Doses: A Suggested Warfarin Dosing Algorithm

被引:6
作者
Khaleqsefat, Esmat [1 ]
Khalaj-Kondori, Mohammad [1 ]
Bonyadi, Mortaza Jabarpour [1 ]
Soraya, Hamid [2 ]
Askari, Behnam [3 ]
机构
[1] Univ Tabriz, Dept Anim Biol, Fac Nat Sci, Tabriz, Iran
[2] Urmia Univ Med Sci, Dept Pharmacol, Fac Pharm, Orumiyeh, Iran
[3] Urmia Univ Med Sci, Seyyed Al Shohada Heart Ctr, Dept Cardiovasc Surg, Orumiyeh, Iran
来源
IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH | 2020年 / 19卷 / 03期
关键词
VKORC1; CYP2C9; Genetic Polymorphism; Warfarin; Demographic Characteristics; REQUIREMENTS; PHARMACOLOGY; ASSOCIATION; MUTATIONS; GENOTYPES; THERAPY; IMPACT;
D O I
10.22037/ijpr.2020.1101116
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The requirement of varying doses of warfarin for different individuals can be explained by environmental and genetic factors. We evaluated the frequency of vitamin K epoxide reductase complex subunit 1 (VKORC1) and cytochrome P450 2C9 (CYP2C9) variants together with patientdemographic characteristics and investigated their association with warfarin dose requirement with the objective to suggest a warfarin dosing algorithm. In this study, 185 patients with heart valve replacement from West Azerbaijan, Iran were genotyped for VKORC1 (-1639 G A) and CYP2C9 (*2 and *3 alleles) by PCR-RFLP. Multiple linear regression was performed to create a new warfarin dosing algorithm. The frequency of variants in studied subjects was 12% for CYP2C9 *2, 25.8% for CYP2C9 *3, and 60% for-1639A. The patients who carried the A allele at position-1639 VKORC1 and the variants CYP2C9 *2 and *3 required a significantly lower daily mean warfarin dosage (P = 0.001). Statistical analysis also indicated a significant relationship between the daily maintenance dose of warfarin with age and blood pressure among the studied patients' cohort (P < 0.001). This study showed that in the heart valve replacement patients considering VKORC1 and CYP2C9 polymorphisms beside demographic characteristics such as age will be helpful in pre-treatment dosing of warfarin which in turn reduces the complications associated with inappropriate warfarin dosing.
引用
收藏
页码:77 / 85
页数:9
相关论文
共 30 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[3]   Study on a novel polymorphism in the VKORC1 promoter region using bioinformatic tools and warfarin dosing data [J].
Askari, Behnam ;
Khaleqsefat, Esmat ;
Khalafkhani, Davood ;
Khalaj-Kondori, Mohammad ;
Khademvatan, Kamal ;
Soraya, Hamid .
THROMBOSIS RESEARCH, 2017, 158 :76-78
[4]   Novel VKORC1 Mutations Associated with Warfarin Sensitivity [J].
Baniasadi, Shadi ;
Beizaee, Samira ;
Kazemi, Bahram ;
Behzadnia, Neda ;
Shafaghi, Bijan ;
Bandehpour, Mojgan ;
Fahimi, Fanak .
CARDIOVASCULAR THERAPEUTICS, 2011, 29 (04) :E1-E5
[5]   A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance [J].
Bodin, L ;
Horellou, MH ;
Flaujac, C ;
Loriot, MA ;
Samama, MM .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (07) :1533-1535
[6]   Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose:: a prospective study [J].
Carlquist, John F. ;
Horne, Benjamin D. ;
Muhlestein, Joseph B. ;
Lappe, Donald L. ;
Whiting, Bryant M. ;
Kolek, Matthew J. ;
Clarke, Jessica L. ;
James, Brent C. ;
Anderson, Jeffrey L. .
JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2006, 22 (03) :191-197
[7]   A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [J].
D'Andrea, G ;
D'Ambrosio, RL ;
Di Perna, P ;
Chetta, M ;
Santacroce, R ;
Brancaccio, V ;
Grandone, E ;
Margaglione, M .
BLOOD, 2005, 105 (02) :645-649
[8]  
Daly Ann K, 2006, Methods Mol Biol, V320, P193
[9]   Effect of Genetic Variants, Especially CYP2C9 and VKORC1, on the Pharmacology of Warfarin [J].
Fung, Erik ;
Patsopoulos, Nikolaos A. ;
Belknap, Steven M. ;
O'Rourke, Daniel J. ;
Robb, John F. ;
Anderson, Jeffrey L. ;
Shworak, Nicholas W. ;
Moore, Jason H. .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2012, 38 (08) :893-904
[10]   Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation [J].
Gong, Inna Y. ;
Schwarz, Ute I. ;
Crown, Natalie ;
Dresser, George K. ;
Lazo-Langner, Alejandro ;
Zou, GuangYong ;
Roden, Dan M. ;
Stein, C. Michael ;
Rodger, Marc ;
Wells, Philip S. ;
Kim, Richard B. ;
Tirona, Rommel G. .
PLOS ONE, 2011, 6 (11)